Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TRABECTEDIN Cause Malignant neoplasm progression? 38 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 38 reports of Malignant neoplasm progression have been filed in association with TRABECTEDIN (YONDELIS). This represents 1.9% of all adverse event reports for TRABECTEDIN.

38
Reports of Malignant neoplasm progression with TRABECTEDIN
1.9%
of all TRABECTEDIN reports
15
Deaths
13
Hospitalizations

How Dangerous Is Malignant neoplasm progression From TRABECTEDIN?

Of the 38 reports, 15 (39.5%) resulted in death, 13 (34.2%) required hospitalization, and 2 (5.3%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TRABECTEDIN. However, 38 reports have been filed with the FAERS database.

What Other Side Effects Does TRABECTEDIN Cause?

Neutropenia (207) Anaemia (189) Thrombocytopenia (172) Nausea (160) Febrile neutropenia (142) Pancytopenia (124) Vomiting (121) Rhabdomyolysis (117) Off label use (105) Alanine aminotransferase increased (104)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which TRABECTEDIN Alternatives Have Lower Malignant neoplasm progression Risk?

TRABECTEDIN vs TRACLEER TRABECTEDIN vs TRADJENTA TRABECTEDIN vs TRALOKINUMAB-LDRM TRABECTEDIN vs TRAMADOL TRABECTEDIN vs TRAMADOL\TRAMADOL

Related Pages

TRABECTEDIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression TRABECTEDIN Demographics